M yasthenia gravis (MG) is an acquired disease of the neuromuscular junction characteri i ized by muscular weakness and fatigability. The prevalence of MG is 50 to 125 persons per million in Western countries, with the incidence peaking after 60 years of age in males and before 40 years of age in fei i males. 1, 2 Longiterm treatment of MG includes the use of cholinesterase inhibitors, steroids, immunosuppresi i sive agents and thymectomy, while shortiterm use of plasma exchange or IV immunoglobulin is reserved for patients with crises or severe weakness. 3 An evidencei based review failed to show the benefits of thymectomy in nonithymomatous MG, despite its widespread use in this subgroup of patients. 4 Racial factors influence the natural history of MG to a variable extent in different societies. For instance, Chinese and black South Africans are more likely to present with ocular MG compared to whites 5 and white South Africans. 6 Yet, few studies have attempted to dei i lineate the clinical profile of MG amongst peoples of Background and oBJEcTIVES: Few studies have attempted to delineate the clinical profile of myasthenia gravis (MG) among people of Arab ancestry. Therefore, we sought to clarify the clinical profile, the outcome of treatment and the role of thymectomy in non-thymomatous MG in Saudi Arabia.
PaTIEnTS and METhodS:
We retrospectively studied 104 patients followed over a mean period of 7.2 years (range, 1 to 22 years) at the King Khaled University Hospital, Riyadh, Saudi Arabia. Disease outcomes were compared among thymectomized and non-thymectomized patients according to the post-intervention status criteria of the Myasthenia Gravis Foundation of America (MGFA). rESulTS: Age of onset was 22.5±9.3 years (mean±SD) in females and 28.2±15.9 years in males, with peaks in the second and third decades among females and the third and fourth decades among males. At diagnosis, a majority of patients had moderate generalized weakness, equivalent to MGFA class III severity. After medical treatment with or without thymectomy, 9.6% of all patients had achieved complete stable remission, 3.8% had pharmacological remission, 27.9% had minimal manifestations, 23.1% were improved, 20.2% were unchanged and 15.4% were worse. Only thymectomized patients without a thymoma achieved remission, a significant benefit over those who had no thymectomy (P=.02). concluSIon: MG presents at a younger age among Saudi Arabs compared to other racial groups. Thymectomy conferred significant benefits towards achievement of remission. Arab ancestry. One study from Saudi Arabia discussed the benefits of thymectomy in 48 patients followed for 20 months, 7 while a study from Oman described outi i comes in 50 patients followed for three years. 8 In both studies, data were not subjected to statistical analysis, there were no control groups, and followiup periods were relatively short for a disease characterized by fluci i tuating severity. To clarify the clinical profile of MG, the outcome of treatment and the role of thymectomy in nonithymomatous MG, we conducted a retrospective study of all cases of MG seen at our hospital from 1984 to 2006.
PaTIEnTS and METhodS
Records of all patients diagnosed with MG at the King Khaled University Hospital, Riyadh, from 1984 to 2006 were reviewed. The diagnosis of MG was based on one or more of the following criteria: the presence of fluctuating muscle weakness with early fatigability, improvement in signs and symptoms after IV edroi i phonium, a decremental response on repetitive nerve stimulation (RNS) and the presence of serum antibodi i ies to the acetylcholine receptor. Patients were included in the study if they had followiup records of one year or more. Records reviewed included biographic data, symptoms and signs at presentation and followiup and results of investigations that included chest CT scans, thymus histology and muscle biopsy in selected cases. Histological findings of the thymus were classified as hyperplastic, thymomatous, atrophied or normal.
Disease severity at presentation was classified accordi i ing to the Myasthenia Gravis Foundation of America (MGFA) clinical classification: 9 grade 0, no symptoms; grade I, ocular muscle weakness only; grade II, mild generalized weakness; grade III, moderate generalized weakness; grade IV, severe generalized weakness; grade V, intubation required. Treatments usually began with pyridostigmine, which was titrated to a maximum dose of 240 mg daily if this was not limited by side effects. When symptoms did not improve, prednisolone was started at a dose of 0.8mg/kg and subsequently tapered to a maintenance dose of 5i15 mg per day. When higher maintenance doses were required or steroids were not tolerated, such as in those with diabetes mellitus, azai i thioprine (50i150 mg daily) was used. Thymectomy was offered to all patients irrespective of disease severi i ity or chest CT findings. Assessment of outcome was based on the MGFA postiintervention status criteria (PIS) at last outpatient or emergency visit. 9 Patients were classified as having achieved complete stable rei i mission (CSR), pharmacological remission (PR), minii i mal manifestations (MM), had unchanged severity (U), had worse severity (W) or had died (D) from MG. We further grouped CSR, PR and MM as satisfactory outi i comes and all other PIS classes as poor outcomes. The three primary endpoints were the achievement of CSR, any remission (either CSR or PR) and a satisfactory outcome.
Data were analyzed with SPSS for Windows softi i ware version 11.5. The unpaired t test was used for coni i tinuous variables while the chi square and Fisher exact tests were used to compare proportions, with P values <.05 considered significant.
rESulTS

All patients
One hundred and four patients were studied, consisting of 40 males and 64 females (M:F ratio=1:1.6). Age at diagnosis of MG ranged from 3 to 73 years, with a mean (±SD) of 22.5±9.3 years in females and 28.2±15.9 years in males, a difference that was statistically significant (P=.024). Peaks of onset were in the second and third decades in females and the third and fourth decades in males. Only one male and no female had disease onset beyond the sixth decade, while four males and three fei i males were diagnosed within the first decade. Duration of followiup ranged from 1 to 22 years (7.6±4.6 years), with 29% of patients having 10 years followiup or more. At diagnosis (Figure 1 The prevalence of acetylcholine receptor antibodies in those with disease onset younger than age 14 years (10/15, 67%) was similar to that of adultionset MG (61/82, 74%). Four of the five seronegative patients with childhoodionset MG had muscle biopsies, which excluded mitochondrial disease and muscular dystroi i phies. Twentyisix patients (25%) had other autoimi i mune diseases, with thyroid disease being most comi i mon (Table 1) . At last assessment, 10 patients (9.6%) were in CSR, four patients (3.8%) in PR, 29 patients (27.9%) had MM, 24 patients (23.1%) had significant improvement, 21 patients (20.2%) had unchanged sei i verity and 16 patients (15.4%) were worse ( Figure 2) . No patient died of MG during the period of study.
Thymectomized versus non-thymectomized patients
Thymectomy was performed in 81 patients (78%), at a median interval of one year from MG diagnosis (range, 2 months to 6 years). Seventyitwo of these patients had maximal thymectomy by the transisternal approach, while nine patients had laparoscopic surgery. Histology results were not available for two patients. Of the rei i maining 79 patients, hyperplasia was seen in 54 (68.4%), an atrophied or normal thymus in 17 (21.5%) and thyi i moma in 8 patients (10.1%). Remission was achieved only by patients who had thymectomy, at a mean ini i terval of 26 months (range, 3 to 72 months) from thyi i mectomy and 46 months (range, 9 to 84 months) from MG diagnosis. Duration of remission at last assessment ranged from 1 year to 18 years (mean, 5 years).
To assess the benefits of thymectomy in nonithyi i momatous MG, 8 patients with thymoma were exi i cluded from the analysis. The rate of CSR in thymectoi i mized patients was not significantly different from noni thymectomized patients (13.7 % vs. 0.0%; P=.111), but the achievement of any remission (either CSR or PR) was significantly higher in patients who had thyi i mectomy compared to those who had no thymectomy (19.18% vs. 0.0%; P=.02).
Patients seronegative for acetylcholine receptor antibodies tended to have better remission rates comi i pared to seropositive patients (19.23% v. 11.2%), but this difference was not significant (P=.325). No differi i ence was observed in age of onset between those who did and those who did not achieve CSR, any remission or a satisfactory outcome. A higher rate of satisfactory outcome was observed among thymectomized patients (46.6% vs. 26.1%; P=.095), but this difference was not significant. The differences in requirements for steroids or azathioprine were also not significant ( Table 2 ). 
dIScuSSIon
Our results show that MG in Arabs occurs at an age younger than in other racial groups, 9, 10 findings that are consistent with previous studies. 7, 8 We did not observe the second peak of onset beyond age 50 years described in European males or in patients with thymoma, 10 as the mean age of our thymoma patients was 38.2 years. The younger age of onset observed in our patients may raise the possibility of other childhood diseases mimi i icking autoimmune MG. However, since most of our patients with disease onset younger than age 14 years had high titers of acetylcholine receptor antibodies, and four of five seronegative patients had muscle biopsies, disorders such as muscular dystrophies, mitochondrial disease and congenital myasthenic syndromes were efi i fectively excluded.
The prevalence of acetylcholine receptor antibodies in MG varies greatly between studies, depending on the patient population. Rates of 94% in adultionset generali i ized MG and 29% in pure ocular MG have been reporti i ed among whites, 10 while in a Chinese cohort composed of both adults and children, the rates were 85% in generi i alized MG and 59% in purely ocular MG. 11 In exclusivei i ly pediatric MG populations, reported prevalence rates have ranged from 33% to 81%. 12, 13 Thus, seroprevalence rates among the different subgroups in the present study were all within the ranges reported elsewhere.
Over half of our patients presented with either modi i erate or severe disease, but after medical treatment with or without thymectomy, 41% had a satisfactory outi i come, 23% had significant improvement and 13% had achieved some form of remission. More significant is the benefit of thymectomy observed among our patients. All 14 patients who achieved either CSR or PR had had thymectomy, compared to nonithymectomized patients who achieved neither, a difference that was significant. If the decision to perform thymectomy was influenced by disease severity in our patients, this could poteni i tially bias our results, but thymectomy at our center was offered to all patients so that nonithymectomized patients were those that refused surgery. A very large Italian study 14 reported a remission rate of 11%, which was comparable to our own findings, but other studies have reported better remission rates, depending on crii i teria used to define remission. For instance, an Italian study reported a siximonth CSR rate of 9.5%, 15 while remission rates were 34% among thymectomized pai i tients versus 17% among nonithymectomized patients in a Japanese study, 16 even though some of the patients in the latter study continued to take anticholinesterases. However, the MGFA postiintervention status criteria used in our study defines CSR as the absence of sympi i toms and signs of MG for at least one year in a patient who received no therapy during that period. 8 Contrary to findings in many studies, 17i19 but coni i sistent with the results of one study, 15 we did not find a younger age at onset having favorable effects on rei i mission among our patients with nonithymomatous MG. We did observe, however, that patients who had thymectomy in our study were a decade younger than those who did not have thymectomy, suggesting that eii i ther younger patients were more likely to give consent to surgery, or surgery was more likely when someone other than the patient gave consent, as in the case of children.
Our study had some limitations, mainly due to its retrospective design. For instance, some investigation results could not be traced, although this could be due to the long followiup as much as the retrospective dei i sign. We observed also that some patients with minimal or no symptoms continued to take anticholinesterases, perhaps due to lack of clear criteria for stopping drug treatment, a situation that would not arise in a prospeci i tive study. Although this could negatively influence outi i comes, we do not believe that the effect was significant, considering the very small number of such patients among our cohort.
In conclusion, our results show that MG presents at a much younger age among Arabs compared to other rai i cial groups, but the clinical profile and response to theri i apy is comparable to results obtained elsewhere. While we observed a striking benefit of thymectomy among patients with nonithymomatous MG, over 35% of all patients had unfavorable outcomes at last assessment. Clearly, early diagnosis and timely referral to specialist centers for optimal therapy and thymectomy may result in a better prognosis. The high prevalence of thyroid disi i ease among MG patients should alert physicians to the possibility of coiexisting myopathy, especially among patients who do not respond to optimal therapy.
